After Roche data, Morgan Stanley says Viking VK2735 has best-in-class potential

After data for Roche’s (RHHBY) CT-996 oral weight loss drug candidate were presented at the European Association for the Study of Diabetes, or EASD, annual meeting, Morgan Stanley says a comparison of Viking Therapeutics’ (VKTX) initial VK2735 data to Roche’s detailed CT-966 data suggests a potential tolerability advantage for Viking. The firm, which expects updated Phase 1 data for VK2735 at higher doses at Obesity Week in early November to support greater weight loss and a tolerable safety profile, continues to believe VK2735 has “best-in-class potential.” The firm reiterates an Overweight rating and $105 price target on Viking shares.